Galapagos to Use GeneGo's MetaCore Software in Drug Development Research | GenomeWeb
NEW YORK (GenomeWeb News) — GeneGo today said that Galapagos will use its MetaCore software for internal research across “several disease areas” including osteoporosis, osteoarthritis, and rheumatoid arthritis.
 
Galapagos has previously used its adenoviral technology to identify and validate targets in bone and joint diseases, and applying MetaCore to these targets “could allow us to gain valuable insights at the system level,” Galapagos said in a statement.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.